Adding neratinib, an irreversible pan-HER tyrosine kinase inhibitor, after neoadjuvant and adjuvant anti-HER2 treatment for patients with stage 2-3 HER2 + tumor resulted in favorable prognosis; hazard ratio: 0.58, 95% confidence interval: 0.41-0.82, P = 0.002 for 5-year invasive DFS, hazard ratio: 0.79, 95% confidence interval: 0.55-1.13, P = 0.203 for OS; but in HR +/HER + group the results were; hazard ratio: 0.60, 95% confidence interval: 0.33-1.07, P = 0.086 for 5-year invasive DFS, hazard ratio: 0.47, 95% confidence interval: 0.23-0.92, P = 0.031 for OS (39). The gene discussed is ERBB2; the disease is neoplasm.